ARCHIVES

Phase III Trial Data: Lenvatinib Extends PFS by Over 14 Months

This article is from The Cancer Letter archive.

Vol. 37 No. 6 | June 27, 2014

Download PDF Visit The Full Archive

Related Articles

Boyd’s Rebuttal to DePinho’s Letter to the AAUP

May 30, 2014

“Soft Soap” Comprehensive Center Review Still Stung Some; NSAB Left With Perplexing Situations

May 26, 1978

FDA Rile Changes Reporting Requirements for Adverse Events

November 18, 1994

In Brief: Schilsky Named ASCO Chief Medical Officer

November 1, 2012

Tissue of Origin Test Consistent With Diagnosis In Blinded Validation Study

January 28, 2011

IOM Calls FDA Advisory System Sounds, Suggests Conflict Criteria Changes

March 5, 1993